Here are the 10-K annual reports from Anika Therapeutics Inc (ANIK) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ANIK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIK filings page.
Anika Therapeutics outlines a major strategic shift toward osteoarthritis (OA) pain management and regenerative orthopedic solutions built on its hyaluronic acid (HA) technology. The company has exited earlier acquisitions by selling Arthrosurface for a ten‑year, non‑interest‑bearing $7.0 million promissory note plus potential contingent payments, and Parcus Medical for $4.5 million in cash, sharpening focus on higher‑priority HA programs.
Growth is centered on OA products Monovisc and Orthovisc, marketed in the U.S. through a long‑standing exclusive partnership with J&J MedTech, which accounted for 50% of 2025 revenue, and on the Integrity Implant System for tendon augmentation, which is gaining surgical adoption. Anika is advancing Cingal toward a U.S. NDA with ongoing bioequivalence work and pursuing FDA approval of Hyalofast after submitting a PMA, though the FDA has issued a deficiency letter the company is working to address. Research and development spending rose to $25.8 million in 2025 to support these regulatory and clinical programs, while the 10‑K also highlights competitive pressures, manufacturing and supply‑chain concentration, heavy customer reliance, and extensive global regulatory, reimbursement, cybersecurity, data‑privacy, and product‑liability risks.